Kadcyla, R & D daily, became the first antibody coupling drug approved in China

Haizheng heavy pneumonia drug was approved; evoke stomach disease new drug was re submitted to the market and accepted; Glaxo BCMA ADC obtained the priority approval qualification; two oncogenes may cooperate to promote the progress of cancer metastasis We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Today, Haizheng Pharmaceutical Co., Ltd announced that recently, Hanhui pharmaceutical, a holding subsidiary of Haizheng Pharmaceutical Co., Ltd., received the supplementary application approval document of piperacillin sodium and tazobactam sodium for injection (specification 4.5g (piperacillin 4.0g and tazobactam 0.5g), trade name "tezhixing") approved and issued by the State Food and drug administration Today, horizon therapeutics announced that the US FDA has approved its innovative treatment tepezza for the treatment of thyroid ophthalmopathy It is worth mentioning that this is the first approved treatment for this rare eye disease! Moreover, this approval is more than a month ahead of the expected date! Today, Evoke Pharma, which focuses on the development of gastrointestinal medicine, announced that the US FDA had accepted the new drug application of its Gimoti nasal spray which was re submitted It is expected that FDA will respond in June 19th of this year On the 21st, Roche kadcyla's application for listing in China (jxss1900012 / 3) was officially approved by nmpa The single drug was used for adjuvant treatment of HER2 positive early breast cancer patients with residual invasive lesions after new adjuvant treatment based on taxanes combined with trastuzumab, becoming the first antibody coupling drug approved for listing in China Glaxo today announced that belantamab mafodotin (gsk2857916), its BCMA antibody-j6m0-mcmmaf coupling drug, is qualified for FDA priority approval Johnson & Johnson's Janssen Pharmaceutical recently announced that the European Commission has approved the combination of darzalex with bortezomib, thalidomide and dexamethasone (VTD) for the first-line treatment of newly diagnosed patients with multiple myeloma who meet the conditions of autologous stem cell transplantation Jazz pharmaceutical recently announced that the European Commission has approved sunosi for the treatment of excessive daytime sleepiness in adults related to narcolepsy or obstructive sleep apnea.